Literature DB >> 24383114

Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.

John W Kunstman, Reju Korah, James M Healy, Manju Prasad, Tobias Carling.   

Abstract

BACKGROUND: Epigenetic alterations such as DNA methylation are widespread cancer, contributing to tumorigenesis and acting as markers for prognostication. Papillary thyroid cancer (PTC) demonstrates tumor-specific methylation of numerous genes, including RASSF1A. Although the function of RASSF1A in PTC tumorigenesis is still being defined, quantitative evaluation of RASSF1A methylation and its correlation with tumor characteristics has not been performed.
METHODS: Analysis of RASSF1A methylation was performed using quantitative polymerase chain reaction after methylation-dependent and -sensitive restriction enzyme digestion in PTC (n = 41) and normal (n = 18) thyroid tissue. Methylation was then evaluated for correlation with tumor size, stage, and multiple histopathologic characteristics.
RESULTS: RASSF1A promoter hypermethylation was observed in nearly all PTC cases versus normal thyroid tissue, with mean hypermethylation 4.2 times greater in PTC (P < .05). Hypermethylation was greater in multifocal than unifocal PTC (P < .05). Furthermore, tumor methylation was inversely correlated with extracapsular invasion (P < .05).
CONCLUSION: RASSF1A methylation differs in PTC compared with normal thyroid, is associated with multifocality, and is inversely correlated with extracapsular invasion. The ease of evaluating methylation status with minute amounts of DNA suggests a potential role for RASSF1A as a molecular marker for characterization of PTC histopathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24383114     DOI: 10.1016/j.surg.2013.06.025

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

2.  Dynamic Changes of Fetal-Derived Hypermethylated RASSF1A and Septin 9 Sequences in Maternal Plasma.

Authors:  Li Zhang; Chen-Mei-Yi Wang; Wei-Ping Zhou; Qiu-Ping Chen; Shuai Zhou; Wen Lei; Hua Deng; Liang Zhang; Guo-Cheng Liu
Journal:  Reprod Sci       Date:  2021-01-08       Impact factor: 3.060

3.  DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma.

Authors:  Taylor C Brown; C Christofer Juhlin; James M Healy; Adam Stenman; Jill C Rubinstein; Reju Korah; Tobias Carling
Journal:  Surgery       Date:  2015-10-09       Impact factor: 3.982

4.  The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).

Authors:  Heng Niu; Jingyu Yang; Kunxian Yang; Yingze Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

Review 5.  Epigenetic modification and BRAF gene mutation in thyroid carcinoma.

Authors:  Guo Huang; Juan Chen; Jun Zhou; Shuai Xiao; Weihong Zeng; Jiliang Xia; Xi Zeng
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.